Evidence map›Paper›PMID 42465291›Full record

ArticlebioRxiv : the preprint server for biology2026

A Multidimensional Analysis of the Bimodal Piperaquine Response in

John Kane, Aubrey Schall, Lisa A Checkley, Douglas A Shoue, Sydney M Gavula, Caroline Thomas, Xue Li, Ian H Cheeseman, Ashley M Vaughan, Timothy J Anderson and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

John KaneDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.ORCID 0000-0003-4917-7205
Aubrey SchallDept. of Chemistry and Dept. of Biochemistry and Cellular and Molecular Biology, Georgetown University, Washington, D.C., USA.
Lisa A CheckleyDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.
Douglas A ShoueDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.
Sydney M GavulaDepartment of Chemistry, The Pennsylvania State University, University Park, Pennsylvania, USA.
Caroline ThomasDept. of Chemistry and Dept. of Biochemistry and Cellular and Molecular Biology, Georgetown University, Washington, D.C., USA.
Xue LiDisease Intervention and Prevention Program, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Ian H CheesemanHost Pathogen Interactions Program, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Ashley M VaughanCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Timothy J AndersonDisease Intervention and Prevention Program, Texas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0002-0191-0204
Manuel LlinásDepartment of Chemistry, The Pennsylvania State University, University Park, Pennsylvania, USA.
Paul D RoepeDept. of Chemistry and Dept. of Biochemistry and Cellular and Molecular Biology, Georgetown University, Washington, D.C., USA.
Michael T FerdigDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.

Funding

Systems genetics of artemisinin resistanceP01AI127338 · NIAID · UNIVERSITY OF NOTRE DAME · PI Michael T Ferdig · 2017 to 2026
$21.3M
NIAID NIH HHS P01 AI127338Wellcome Trust
6 · The paper itself

Abstract

Malaria remains a pressing global health challenge, with the continued emergence of resistance threatening the long-term efficacy of artemisinin-based combination therapies (ACTs). Piperaquine (PPQ), an important partner drug in artemisinin-based combination therapies exhibits a unique bimodal dose-response phenotype associated with reduced susceptibility, yet the biological mechanism underlying this phenotype remains unknown. This phenotype is strongly associated with mutations in pfcrt and copy number amplification of

Identifiers

PMID42465291
PMCPMC13370493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.